Suppr超能文献

塞来昔布作为一种新型有前途的疼痛治疗药物。

Cebranopadol as a Novel Promising Agent for the Treatment of Pain.

机构信息

Chair and Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Doktora Witolda Chodźki Street, 20-400 Lublin, Poland.

出版信息

Molecules. 2022 Jun 21;27(13):3987. doi: 10.3390/molecules27133987.

Abstract

Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the nociceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.

摘要

阿片类药物被用于治疗疼痛,但尽管它们具有疗效,却存在一些副作用,如呼吸抑制、耐受和身体依赖。塞来昔布被评估为解决这一问题的一种方法。该化合物作用于μ阿片受体和孤啡肽/孤啡肽受体,这些受体的共同激活可以减少阿片类药物的副作用,而不影响镇痛效果。在本综述中,我们收集了关于塞来昔布的作用、药代动力学以及涉及塞来昔布的临床试验的信息,以进一步探讨其在疼痛管理中的应用前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/740b/9268744/ffd00b2ab8fc/molecules-27-03987-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验